Academisch Ziekenhuis Leiden — Sponsor Intelligence | 22 EU Trials

Filter these 22 trials by condition, phase, country and more.

Open in Search →

22 Registered trials

17 Recruiting

4 Completed trials

6 Countries active

31 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 4 Phase II/III: 2 Phase II: 7 Phase I/II: 1 Phase III/IV: 2 Phase IV: 5 Phase I (Other): 1

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Anti-HLA antibody test positive 1 Systemic lupus erythematosus 1 Hyperkalaemia 1 Glomerulonephritis 1 Diabetes mellitus 1 Transplant rejection 1

Top IMPs

CHIMERIC MONOCLONAL ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN CONJUGATED TO FLUOROCHROME BM-104 4 BELIMUMAB 2 RITUXIMAB 2 ALFACALCIDOL 1 CAPECITABINE 1 CEFUROXIME 1 CYCLOPHOSPHAMIDE 1 ESKETAMINE 1 FENTANYL CITRATE 1 FLUOROURACIL 1 FOLINIC ACID 1 HUMAN COAGULATION FACTOR IX, PROTEIN C, HUMAN COAGULATION FACTOR VII, PROTEIN S, HUMAN COAGULATION FACTOR II, HUMAN COAGULATION FACTOR X 1

All trials

22 total

Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD) Pending

2023-510312-40-00 Phase IV 1 country ALFACALCIDOL
BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to suppo… Recruiting

2023-508116-32-00 Phase II 1 country BELIMUMAB
Esketamine nasal spray (Spravato) for the treatment of therapy-resistant bipolar depression. An open-label pilot trial. Recruiting

2023-508125-27-00 Phase II 1 country ESKETAMINE
Clear-Brain: stimulating amyloid clearance in cerebral amyloid angiopathy Recruiting

2023-506128-10-00 Phase II 1 country
The impact of vaccine platform, age and HIV infection on germinal centre formation. Recruiting

2023-510354-16-00 Phase III/IV 1 country PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIU…
The effect of a booster vaccination on protection against the mpox virus: is a booster vaccination with a lower dose as effective as the sta… Recruiting

2024-510697-24-00 Phase II/III 1 country MODIFIED VACCINIA ANKARA – BAVARIAN NORDIC LIVE VIRUS
Tolerogenic dendritic cell therapy in type 1 diabetes; a phase 1b safety and immunological effecitivity study Recruiting

2023-508558-25-01 Phase I/II 1 country
DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting

2023-510186-98-00 Phase IV 1 country HUMAN COAGULATION FACTOR IX, PROTEIN C, HUMAN COAGULATION FACTOR VII, PROTEIN S,…
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Phase III 1 country CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN
Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis Recruiting

2023-510480-35-00 Phase IV 1 country RABIES VIRUS (INACTIVATED) STRAIN FLURY LEP
MethMax trial Recruiting

2023-507714-27-00 Phase IV 6 countries METHOTREXATE
SGM-T1: SGM-101 tumor targeted fluorescence endoscopy in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia Recruiting

2024-510769-41-00 Phase II 1 country CHIMERIC MONOCLONAL ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN CONJUGATED TO FLUO…
A feasibility study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for the intraoperative detection of… Recruiting

2024-510767-30-00 Phase II 1 country CHIMERIC MONOCLONAL ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN CONJUGATED TO FLUO…
(SPARROW) Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple’s procedure (SPARROW): a … Recruiting

2024-510766-16-00 Phase III/IV 1 country CEFUROXIME; METRONIDAZOLE
PAmidronate for Pain in Sternocostoclavicular hyperostosis: the PAPS-study, a double-blind randomized placebo-controlled trial Recruiting

2023-510309-16-00 Phase III 1 country PAMIDRONATE DISODIUM; SODIUM CHLORIDE
SGM-LARRC: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carc… Recruiting

2024-510768-21-00 Phase II 1 country CHIMERIC MONOCLONAL ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN CONJUGATED TO FLUO…
Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients Recruiting

2023-507868-39-00 Phase IV 1 country CYCLOPHOSPHAMIDE; RITUXIMAB
A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythemat… Recruiting

2023-507867-20-00 Phase II/III 1 country BELIMUMAB; RITUXIMAB
Dose-finding and safety study of a new Shigella vaccine combined with an adjuvant in the Netherlands and Zambia Ended

2023-506394-35-02 Phase I (Other) 1 country
LIBERAL Study Ended

2023-507823-52-00 Phase III 1 country SODIUM ZIRCONIUM CYCLOSILICATE
The effect of fentanyl on breathing Ended

2023-508915-22-00 Phase III 1 country FENTANYL CITRATE; NALOXONE HYDROCHLORIDE
FLUOPANC II: A performance study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for fluorescence-guide… Ended

2023-510481-27-00 Phase II 1 country CHIMERIC MONOCLONAL ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN CONJUGATED TO FLUO…

Showing 1–22 of 22 trials

← All sponsors A–Z